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ABSTRACT
Background: Granulocyte–macrophage colony-stimulat-
ing factor (GM-CSF) has been implicated as an important
mediator in the pathogenesis of asthma and chronic
obstructive pulmonary disease (COPD). However, the
expression of GM-CSF and its receptor in airway samples
in asthma and COPD across disease severity needs to be
further defined.
Methods: Sputum GM-CSF was measured in 18 control
subjects, 45 subjects with asthma and 47 subjects with
COPD. Enumeration of GM-CSF+ cells in the bronchial
submucosa and airway smooth muscle bundle was
performed in 29 control subjects, 36 subjects with
asthma and 10 subjects with COPD.
Results: The proportion of subjects with measurable GM-
CSF in the sputum was raised in those with moderate (7/
14) and severe (11/18) asthma, and in those with COPD
GOLD (Global Initiative for Chronic Obstructive Lung
Disease) stage II (7/16), III (8/17) and IV (7/14) compared
with controls (1/18) and those with mild asthma (0/13);
p=0.001. The sputum GM-CSF concentration was
correlated with the sputum eosinophilia in subjects with
moderate to severe asthma (rs=0.41; p=0.018). The
median (interquartile range) GM-CSF+ and GM-CSFR+
cells/mm
2 of submucosa was increased in severe asthma
(1.4 (3.0) and 2.1 (8.4)) compared with those with mild to
moderate asthma (0 (2.5) and 1.1 (5)) and healthy
controls (0 (0.5) and 0 (1.6)), (p=0.004 and p=0.02,
respectively).
Conclusions: The findings support a potential role for
GM-CSF in asthma and COPD and suggest that over-
expression of GM-CSF in sputum and the bronchial
mucosa is a particular feature of severe asthma.
The airway diseases asthma and chronic obstruc-
tive pulmonary disease (COPD) are common and
cause significant morbidity and mortality world-
wide. Asthma affects 10% of children and 5% of
adults, and its prevalence continues to rise.
1 Severe
asthma accounts for about 10% of asthma, but is
particularly important as it leads to debilitating
chronic symptoms despite optimal standard
asthma treatment and contributes to over half of
the healthcare costs attributed to asthma.
1–3 COPD
is a major public health problem and will rank as
the third cause of death in 2030.
4 Both conditions
are characterised by airflow obstruction with
airway inflammation, and remodelling. Although
the inflammatory profiles of asthma and COPD
have been described as overlapping,
5 asthma is
more commonly associated with Th2-mediated
eosinophilic inflammation
6 whereas in COPD
neutrophilic inflammation is more predominant.
5
Several cytokines and chemokines have been
implicated in driving the airway inflammatory
response in asthma and COPD.
Granulocyte–macrophage colony-stimulating
factor (GM-CSF) is a major regulator of inflam-
matory cells of the myeloid lineage and has been
implicated in asthma and COPD.
7 It is released by a
range of structural and inflammatory cells, includ-
ing airway epithelium, airway smooth muscle
(ASM), fibroblasts, T lymphocytes, mast cells,
eosinophils and macrophages. GM-CSF has
recently been shown to signal via a ternary
receptor complex (GM-CSFR) composed of a
2:2:2 hexamer consisting of two bc chains, two
GMRa chains and two GM-CSF molecules.
8 GM-
CSF is a pleiotrophic and proinflammatory cyto-
kine that stimulates myelopoiesis, promotes leu-
cocyte survival and activation, and regulates
mucosal immunity and inflammation in part via
modulation of Toll-like receptor-4
9 and neutrophil
function.
10 Its importance in airways disease is
supported by evidence from mouse models of
COPD
7 and asthma,
11 whereby administration of
anti-GM-CSF antibody attenuates the neutrophilic
and eosinophilic inflammatory response, respec-
tively. Importantly, in human disease, GM-CSF
expression is increased in sputum, bronchoalveolar
lavage (BAL) and bronchial biopsies in asthma.
12–17
In contrast, in COPD there is a lack of direct
evidence of increased GM-CSF expression in air-
way secretions or biopsy tissue. However, in
culture, GM-CSF secretion by ex vivo sputum cells
is increased in COPD.
18 Similarly, whether GM-
CSFR expression is increased in airways disease is
contentious, with one study suggesting that GM-
CSFR is increased in non-atopic, but not atopic
asthma.
19 Therefore, GM-CSF and GM-CSFR
expression in airways disease needs to be further
defined.
We hypothesised that GM-CSF and GM-CSFR
expression is increased in asthma and COPD, and is
related to disease severity. To test our hypothesis
we have measured the sputum GM-CSF concen-
tration and enumerated in bronchial mucosa the
number of GM-CSF+ and GM-CSFR+ cells in
asthma and COPD.
METHODS
Subjects
Subjects were recruited from hospital staff, the
general respiratory and the ‘Difficult Asthma’
clinics at Glenfield Hospital, Leicester, local
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defined according to the current Global Initiative for Asthma
(GINA) guidelines.
20 Subjects with asthma had typical symp-
toms and the presence of one or more of the following objective
criteria: significant bronchodilator reversibility of forced epira-
tory volume in 1 s (FEV1) .200 ml, a provocation concentra-
tion of methacholine causing a 20% fall in FEV1 (PC20)o f
,8 mg/ml or a peak flow amplitude percentage mean over
2 weeks of .20%. Asthma severity was classified using the
GINA treatment steps.
20 COPD was diagnosed and severity
categorised by using the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria.
21 Subjects with
COPD who demonstrated partial bronchodilator reversibility
were not excluded. Subjects were recruited as three independent
cross-sectional groups, to assess sputum GM-CSF concentration
in asthma and COPD (group 1); and GM-CSF and GM-CSFR
expression in proximal airways in asthma (group 2) and COPD
(group 3). Subjects were free from exacerbations for at least
6 weeks. Healthy controls had normal spirometry, and some
smokers with .10 pack-year history were included to enable
comparisons between healthy smokers and COPD subjects. All
subjects gave written informed consent, with study approval
from the Leicestershire ethics committee.
Protocol
For all subjects, demographics and spirometry were recorded.
Subjects with asthma and healthy controls in groups 1 and 2
also underwent a methacholine inhalation test using the tidal
breathing method
22 and allergen skin prick tests for
Dermatophagoides pteronyssinus, dog, cat and grass pollen.
Sputum induction using incremental concentrations of neb-
ulised hypertonic saline 3, 4 and 5% each for 5 min was also
performed in all subjects in groups 1 and 2.
23
In group 2, subjects underwent bronchoscopy conducted
according to the British Thoracic Society guidelines,
24 and
biopsies were taken from the right middle and lower lobe
carinae. In group 3, proximal airway samples were collected
from surgical specimens. All bronchial mucosal specimens were
fixed in acetone and embedded in glycomethacrylate as
described previously.
25
Sputum GM-CSF measurement
Sputum was selected, dispersed using the mucolytic dithio-
threitol (DTT) and processed to generate a sputum differential
cell count, and cell-free supernatants were stored at 280uC for
later analysis as described previously.
26
Sputum GM-CSF was measured by ELISA (Caltag-
Medsystems, Buckinghamshire, UK). The lower limit of
detection was 10 pg/g sputum. The GM-CSF assay was
validated in line with European Respiratory Society recommen-
dations to assess the effect of DTT and the recovery of
exogenous spiking with recombinant cytokine.
27 GM-CSF
recovery was not affected by DTT, and recovery of exogenous
spiked GM-CSF was 103% (15%) (n=4).
GM-CSF and GM-CSFR expression in endobronchial biopsies
Sections of 2 mm were cut and stained using monoclonal
antibodies against GM-CSF (clone: BVD2-21C11, Cambridge
BioScience, Cambridge, UK), GM-CSFR (clone: 2B7, a mono-
clonal antibody raised to the extracellular domain of GM-CSFR,
gift from Dr Sleeman. MedImmune, Grant Park, Cambridge,
UK), or appropriate isotype controls (rat immunoglobulin G2a
(IgG2a) (R&D Systems Europe, Abingdon, UK) and mouse IgG1
clone DAK-Go1 (Dako UK, Cambridge, UK), respectively). The
number of positive nucleated cells was enumerated per mm
2 of
bronchial submucosa or ASM bundle by a blinded observer as
described previously.
28 29
Statistical analysis
Statistical analysis was performed using PRISM Version 4.
Parametric data were expressed as mean (SEM), data that had a
normal log distribution were log transformed and described as
geometric mean (95% CI) and non-parametric data were
described as median (interquartile range (IQR)). One-way
analysis of variance (Kruskal–Wallis for non-parametric data)
was used for across-group comparisons, with Tukey and Dunn
post hoc tests for between-group comparisons. x
2 tests were
used to compare categorical data. Correlations were assessed by
Spearman rank correlation coefficients.
RESULTS
Sputum GM-CSF concentration in asthma and COPD
Clinical and sputum characteristics for subjects in group 1 are
shown in table 1. The proportion of subjects with measurable
GM-CSF in the sputum was raised in those with moderate (7/
14) and severe (11/18) asthma, and in those with COPD GOLD
stage II (7/16), III (8/17) and IV (7/14) compared with controls
(1/18) and those with mild asthma (0/13) (p=0.001). The
sputum GM-CSF concentration was increased in subjects with
COPD across severity compared with controls (p=0.02
Kruskal–Wallis; p,0.05 for COPD all severities compared with
controls; fig 1). Similarly, the sputum GM-CSF concentration
was increased in severe asthma compared with mild asthma and
controls, and in moderate asthma compared with mild disease
(p,0.001 Kruskal–Wallis; p,0.05 for between-group compar-
isons; fig 1). The sputum GM-CSF concentration was increased
in the subjects with moderate and severe asthma combined
compared with those with COPD GOLD II–IV combined
(p=0.004). The sputum GM-CSF concentration was correlated
with the sputum eosinophilia in subjects with disease as a
whole group (rs=0.28; p=0.007), all those with asthma
(rs=0.3; p=0.04) and moderate and severe disease (rs=0.41;
p=0.018), but not COPD. There was no association in subjects
with asthma or COPD with sputum GM-CSF concentration
and percentage predicted FEV1 (r=20.26, p=0.09; r=20.07,
p=0.7) or the FEV1/FVC (forced vital capacity) ratio (r=0.06,
p=0.7; r=0.1, p=0.5), respectively.
GM-CSF/R expression in large airway tissue specimens
Examples of GM-CSF and GM-CSFR+ cells in the bronchial
submucosa in asthma are as shown in fig 2. Clinical
characteristics of group 2 are as shown in table 2. The median
(IQR) GM-CSF cells/mm
2 of submucosa was increased in severe
asthma (1.4 (3.0)) compared with those with mild to moderate
asthma (0 (2.5)) and healthy controls (0 (0.5)), (p=0.004,
Kruskal–Wallis; between-group comparisons are as shown
fig 3A). The number of GM-CSFR+ cells/mm
2 of submucosa
and ASM was increased in severe asthma (2.1 (8.4) and 2.4 (5.5))
compared with healthy controls (0 (1.6) and 0 (0.8), but not in
those with mild to moderate asthma (1.1 (5) and 1.2 (2.2))
(p=0.02 and p=0.049, respectively, Kruskal–Wallis; p,0.05
severe asthma vs control, fig 3B,C). The number of GM-CSF+
cells in the ASM bundle was very low in subjects with asthma
and healthy controls.
There were no differences in the number of GM-CSF+ or GM-
CSFR+ cells within the submucosa or ASM bundle in lung
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and without a significant smoking history (table 3).
DISCUSSION
We report here for the first time that the sputum GM-CSF
concentration was increased in COPD, independent of disease
severity, and confirm that in asthma the sputum GM-CSF
concentration is associated with more severe disease. In asthma
our sputum findings were supported by increased GM-CSF and
GM-CSFR expression in bronchial biopsies in severe disease.
Our study therefore supports our hypothesis that GM-CSF and
GM-CSFR expression is increased in asthma and COPD, and in
asthma is related to disease severity.
Several lines of evidence support a role for GM-CSF in
COPD. GM-CSF is induced by the presence of airway
pathogens
30 31 and is known to be an important regulator of
the activation and survival of key effector cells in COPD,
namely the neutrophil and macrophage.
32 33 Critically, neu-
tralisation of GM-CSF in animal models attenuates airway
inflammation in response to cigarette smoking.
7 However, to
date there has been a paucity of direct evidence of increased
GM-CSF expression in airway secretions. Indeed the sputum
GM-CSF concentration was not increased in subjects at
exacerbations compared with their stable state at recovery,
34
although in contrast GM-CSF release by sputum cells in
culture was increased.
18 In vivo and in vitro GM-CSF is rapidly
internalised following receptor binding and therefore it is
likely that the measurement of sputum GM-CSF is under-
estimated by ELISA.
73 5Importantly, the concentration of free
GM-CSF is under tight control, with measurable GM-CSF
a u t o a n t i b o d i e si nh e a l t h yc o n t r o l sa sw e l la si nt h o s ew i t h
disease.
36 In spite of this, we here have validated the
measurement of GM-CSF in sputum and found that it was
increased in subjects with COPD across all disease severities
compared with smoking and non-smoking controls, although
there was no relationship between sputum GM-CSF concen-
tration and disease severity. In the resection samples, we were
unable to confirm that expression of GM-CSF or its receptor
was increased. However, we only studied subjects with COPD
with milder disease, and the control subjects often had
underlying lung cancer which may have masked differences
between COPD and controls. Therefore, the role of GM-CSF
in COPD needs to be further defined, and future studies need
to include analysis of bronchial tissue in moderate to severe
COPD.
In asthma there is a wealth of data supporting a role for GM-
CSF. In particular GM-CSF is pivotal in eosinophil maturation
and survival,
37 a key effector cell in asthma. In animal models
Table 1 Group 1: clinical and sputum characteristics of subjects with asthma and chronic obstructive pulmonary disease
Normal
Mild asthma (GINA
1)
Moderate asthma
(GINA 2–4)
Severe asthma
(GINA 5) GOLD II GOLD III GOLD IV
Number 18 13 14 18 16 17 14
Age* 54 (3) 53 (4) 51 (4) 49 (5) 71 (2) 68 (2) 72 (11)
Male/female 4/14 8/5 4/10 7/11 9/7 12/5 13/1
Never/current/ex-smokers 9/0/9 11/0/11 10/0/4 16/0/2 2/9/5 0/6/11 0/4/10
Pack-years* 17 (5) 2 (1) 6 (3) 4 (3) 43 (8) 52 (4) 56 (9)
Atopy, n (%) 6 (33) 7 (54) 11 (79) 13 (72) 7 (44) 7 (41) 5 (36)
PC20FEV1 (mg/ml){ .16 1 (0.3 to 4.2) 0.4 (0.1 to 1.5) 0.1 (0 to 1.6) – – –
FEV1, % predicted* 98.7 (3.0) 80.4 (5.1) 66.4 (4.4) 56.4 (6.8) 60.1 (1.5) 39.9 (1.3) 24.1 (1.3)
Pre-BD FEV1/FVC, %* 77.6 (1.7) 72.1 (3.6) 67.5 (3.0) 69.7 (2.8) 59.4 (2.2) 50.9 (2.1) 40.3 (2.0)
BD response (%)* 1.5 (0.7) 6.0 (3.6) 5.0 (4.6) 9.6 (2.0) 4.3 (2.2) 6.0 (1.8) 4.1 (3.2)
Sputum cell counts
TCC* 3.8 (0.9) 2.34 (0.82) 3.31 (1.8) 6.57 (3.3) 3.3 (0.6) 4.3 (0.9) 11.2 (3.2)
Eosinophils, %{ 0.5 (0.3 to 0.8) 2.3 (0.6 to 7.9) 2.7 (1.0 to 7.3) 3.8 (1.8 to 8.0) 2.3 (1.7 to 6.3) 2.6 (1.4 to 4.7) 1.0 (0.4 to 2.3)
Neutrophils, %* 55.8 (6.0) 67.3 (6.9) 57.8 (5.9) 64.3 (6.0) 72.2 (5.0) 71.0 (4.3) 85.6 (2.9)
Macrophages, %* 38.5 (5.3) 20.6 (4.6) 21.4 (4.7) 19.2 (4.9) 29.2 (4.6) 21.3 (3.3) 8.7 (1.7)
Lymphocytes, %* 0.4 (1.4) 0.5 (0.2) 0.4 (0.1) 1.9 (1.5) 1.6 (1.1) 0.6 (0.2) 1.0 (0.3)
Epithelial cells, %* 3.7 (1.4) 3.7 (1.8) 3.6 (1.7) 3.3 (1.6) 3.3 (0.6) 4.3 (0.9) 11.2 (3.2)
*Mean (SE). {Geometric mean (95% CI).
BD, bronchodilator; FEV1, forced expiratory voume in 1 s; FVC, forced vital capacity; GINA, Global Initiative for Asthma; GOLD, Global Initiative for Chronic Obstructive Lung Disease;
PC, provocation concentration; TCC, total cell count.
Figure 1 Sputum granulocyte–macrophage colony-stimulating factor
(GM-CSF) concentration. Sputum GM-CSF concentration in the control
group, subjects with chronic obstructive pulmonary disease (COPD)
(Global Initiative for Chronic Obstructive Lung Disease (GOLD) II–IV), mild
asthma (Global Initiative for Asthma (GINA) 1), moderate asthma (GINA
2–4) or severe asthma (GINA 5). Across-group comparisons by Kruskal–
Wallis test were p,0.05; p values for Dunn post hoc test for between-
group comparisons are as shown.
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Thorax 2009;64:671–676. doi:10.1136/thx.2008.108290 673Figure 2 Examples of granulocyte–macrophage colony-stimulating factor-positive (GM-CSF+) and GM-CSF receptor-positive (GM-CSFR+) cells in the
submucosa and airway smooth muscle bundle in asthma. Representative photomicrographs of bronchial biopsy sections from subjects with severe
asthma illustrating isotype controls. (A) Rat immunoglobulin 2a (IgG2a), (B) mouse IgG1, (C) GM-CSF+ cells present in the bronchial submucosa and (D)
GM-CSFR+ cells in the submucosa (6400). GM-CSF/R+ cells are highlighted by arrows.
Table 2 Group 2: clinical sputum characteristics of patients with asthma and healthy control subjects
Normal
Mild to moderate asthma
(GINA 1–3)
Severe asthma
(GINA 4–5)
Number 10 15 12
Age* 38 (4) 48 (4) 50 (4)
Male/female 4/6 8/7 6/6
Never/current/ex-smokers 9/0/1 9/0/6 10/0/2
Pack years* 0 (0) 3 (1) 3 (2)
Atopy, (%) 5 (50) 10 (66) 9 (75)
PC20FEV1 (mg/ml){ .16 0.3 (0.1 to 0.4 (0.1 to
FEV1, % predicted* 98.4 (4.5) 89.7 (4.9) 80.2 (6.6)
Pre-BD FEV1/FVC, %* 77.9 (3.3) 74.4 (2.9) 74.5 (3.4)
BD response (%)* 1.1 (1.2) 8.8 (4.1) 12.5 (5.7)
Sputum cell counts
TCC* 2.1 (0.6) 2.9 (0.7) 2.7 (0.6)
Eosinophils, %{ 0.4 (0.1 to 0.8) 0.9 (0.4 to 2.8) 2.9 (0.8 to 10.6)
Neutrophils, %* 48.8 (17.7) 55.2 (7.0) 59 (9.7)
Macrophages, %* 47.4 (11.7) 37.1 (6.3) 25.1 (5.8)
Lymphocytes, %* 1.9 (1.2) 1.1 (0.2) 1.5 (0.7)
Epithelial cells, %* 1.4 (1.2) 4.0 (1.6) 6.9 (3.3)
GM-CSF
Submucosa{ 0 (0.5) 0 (2.5) 1.4 (3.0)
ASM{ 0 (0) 0 (0) 0 (0)
GM-CSFR
Submucosa{ 0 (1.6) 1.1 (5) 2.1 (8.4)
ASM{ 0 (0.8) 1.2 (2.2) 2.4 (5.5)
*Mean (SE). {Geometric mean (95% CI). {Median (interquartile range).
ASM, airway smooth muscle; BD, bronchodilator; FEV1, forced expiratory voume in 1 s; FVC, forced vital capacity; GINA, Global
Iniative for Asthma; GM-CSF, granulocyte–macrophage colony-stimulating factor; GM-CSFR, granulocyte–macrophage colony-
stimulating factor receptor; PC, provocation concentration; TCC, total cell count.
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GM-CSF knockout mice
38 do not develop a bronchial eosino-
philia in response to allergen challenge. In contrast to COPD,
in asthma there are several reports of increased GM-CSF
expression in airway secretions and tissue.
12–17 In particular,
increased sputum GM-CSF expression is associated with more
severe disease.
12 13 We have confirmed these earlier reports and
found that sputum GM-CSF concentration was increased in
moderate to severe asthma, but not in mild disease. In addition
the intensity of the sputum GM-CSF expression was related to
the sputum eosinophilia. We report here for the first time that
GM-CSF and GM-CSFR expression was also increased in the
bronchial submucosa in more severe asthma. Therefore, in
severe asthma there is a generalised upregulation in the
GM-CSF/GM-CSFR axis, suggesting that this mediator may
play a prominent role in severe asthma.
Our study design allowed for direct comparison of the
sputum GM-CSF concentration in asthma and COPD, but not
expression in tissue as samples were obtained using different
methods. Comparisons in sputum GM-CSF concentrations
were undermined by the relative insensitivity of our assay,
with a large number of subjects that had concentrations below
the level of detection of our assay. This is likely to reflect the
rapid internalisation of GM-CSF. In spite of this limitation we
found that sputum GM-CSF was increased in both COPD and
moderate to severe asthma, and importantly it was greater in
moderate to severe asthma than in COPD. Therefore, whether
GM-CSF plays a more important role in severe asthma than in
COPD warrants further investigation.
Our study has a number of possible criticisms. This is a cross-
sectional observational study. We were unable to demonstrate
an association between GM-CSF expression and lung function.
Whether GM-CSF expression is related to longitudinal clinical
outcomes such as disease progression, lung function decline and
exacerbations requires further examination. Similarly, we are
unable to determine whether differences observed between mild
and severe asthma reflect disease severity or are a consequence
of differences in treatment. Therefore, the effects of corticoster-
oids on GM-CSF need to be fully elucidated, although previous
work suggests that GM-CSF expression in tissue is attenuated
by corticosteroids.
39 The rapid turnover of GM-CSF in vivo
limits the interpretation of protein expression by ELISA and
immunohistochemistry. We have not defined the cellular source
of GM-CSF or determined whether the increased expression of
GM-CSF is associated with an increase in the total number of
infiltrating cells within the bronchial submucosa. In addition,
protein expression in tissue often reflects granular stores and
may underestimate GM-CSF expression in cells that release
rather than store GM-CSF, such as T cells. Further studies are
therefore required to confirm our findings and to determine the
relative expression of GM-CSF in bronchial tissue by different
cell types.
In conclusion, we found that the sputum GM-CSF concen-
tration was increased in COPD, independent of disease severity,
and in moderate to severe asthma. Increased bronchial
submucosal expression of both GM-CSF and its receptor was
a particular feature of severe asthma. Our findings therefore do
support a potential role for GM-CSF in asthma and possibly
COPD. Efficacy studies of therapeutic strategies targeted at
GM-CSF are eagerly awaited and will further define the
functional importance of GM-CSF in airways disease.
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Figure 3 The number of granulocyte–macrophage colony-stimulating
factor-positive (GM-CSF+) and GM-CSF receptor-positive (GM-CSFR+)
cells in the submucosa in asthma. The number of (A) GM-CSF+ and (B)
GM-CSFR+ cells in the bronchial submucosa and (C) GM-CSFR+ cells in
the airway smooth muscle bundle in healthy controls, those with mild to
moderate asthma (Global Initiative for Asthma (GINA) 1–3) and those
with severe asthma (GINA 4–5). Across-group comparisons by Kruskal–
Wallis test were all p,0.05; p values for Dunn post hoc test for
between-group comparisons are as shown.
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Table 3 Group 3: clinical characteristics and GM-CSF/GM-CSFR expression in proximal airway from lung
resection
Normal Smoker COPD
Number 8 11 10
Age* 58 (3) 60 (3) 66 (3)
Male/female 7/1 8/3 7/3
Never/current/ex-smokers 6/0/2 0/0/11 0/0/10
Pack-years* 0 (1) 30 (7) 39 (6)
FEV1* 2.8 (0.2) 2.6 (0.2) 1.8 (0.2)
FEV1, % predicted* 87 (3) 87 (4) 64 (4)
Pre-BD FEV1/FVC* 79 (3) 81 (4) 55 (3)
GM-CSF
Submucosa{ 0.5 (1) 0.8 (2.4) 0.2 (1.1)
ASM{ 0 (0) 0 (0.1) 0 (0)
GM-CSFR
Submucosa{ 2.3 (6.1) 0.3 (1.3) 0.5 (4.4)
ASM{ 0 (0.1) 0 (0) 0 (0)
*Mean (SE). {Median (interquartile range).
ASM, airway smooth muscle; BD, bronchodilator; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory voume in
1 s; FVC, forced vital capacity; GM-CSF, granulocyte–macrophage colony-stimulating factor; GM-CSFR, granulocyte–macrophage
colony-stimulating factor receptor; PC, provocation concentration.
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